Managing Adverse Effects
Active Resources: 7
Slide Sets
-
4/9/2020
-
1/31/2020
Antiretroviral Guidelines
-
12/18/2019
Image Library
-
2/20/2019 (reviewed: 2/20/2019)
Online Training
-
10/20/2017
Patient Information
-
10/9/2017
Self-Study Materials
-
2/1/2017
Archive Resources: 2
Videos
-
4/1/2015
Pocket Guides
-
4/1/2015
Articles: 5
-
Weight Gain and Metabolic Complications with ART: Data from AIDS 2020
Over the past few years, numerous studies have examined weight gain in people with HIV who start or change antiretroviral therapy (ART). While it is clear that some people gain excessive amounts of weight after starting (and sometimes upon changing) ART, the roles of specific antiretroviral (ARV...
-
Safety of Dolutegravir at Conception: Updated Data
In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher...
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
Cobicistat and Stribild Use in Patients with Renal Insufficiency
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate...